title: [Isoprostanes - important marker of the oxidative stress estimation in patients with chronic kidney disease].
abstract: The discovery of isoprostanes, which are products of non-enzymatic lipid peroxidation, resulted in the research on the new role of free radicals in physiology and pathophysiology. Isoprostane quantitative analysis is a great achievement in the evaluation of free radical impact on many diseases in human. Isoprostanes were also found to be elevated in end-stage renal disease, another condition associated with increased oxidative stress. The aim of the study was to evaluate the influence of nephroprotective treatments on the urinary excretion of 15-F2alpha-isoprostane in the treated patients with Chronic Kidney Disease (CKD).
  
  
  METHODS
  84 patients (32 females and 52 males); age 18-65 years (average 39.06 +/- 4.92), with chronic non-diabetic proteinuric nephropathy, normal or slightly impaired stable renal function expressed as estimated creatinine cleamace above 30 mi/min, were selected from the cohort that attended our renal outpatients department. Clinical evaluation and laboratory tests were performed at the randomization point and after each period of the study A commercial ELISA Kit (Cayman Chemical Co) was used to measure the urinary excretion of 15-F2alpha-isoprostane in the treated patients.
  
  
  RESULTS
  It was found that the blockade of renin-angiotensin-aldosteron system (with aliskiren, cilazapril, perindopril, spironolakton) and the treatment with atorwastatin significantly reduced urinary levels of 15-F2alpha-isoprostane relatively to the control group. It was not observed for pentoxyfilline treatment.
  
  
  CONCLUSIONS
  Urine levels of isoprostanes are significantly decreased in patients with Chronic Kidney Disease during nephroprotective treatments.
authors.affiliation: Gdański Uniwersytet Medyczny, Katedra i Klinika Nefrologii, Transplantologii i Chorób Wewngtrznych. mrenke@gumed.edu.pl
authors.forename: Marcin
authors.initials: M
authors.lastname: Renke
authors.forename: Narcyz
authors.initials: N
authors.lastname: Knap
authors.forename: Leszek
authors.initials: L
authors.lastname: Tylicki
authors.forename: Przemysław
authors.initials: P
authors.lastname: Rutkowski
authors.forename: Sławomir
authors.initials: S
authors.lastname: Lizakowski
authors.forename: Michał
authors.initials: M
authors.lastname: Woźniak
authors.forename: Bolesław
authors.initials: B
authors.lastname: Rutkowski
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000069059:Atorvastatin; D015415:Biomarkers / Q000652:urine; D005260:Female; D006538:Heptanoic Acids / Q000627:therapeutic use; D006801:Humans; D028421:Isoprostanes / Q000652:urine*; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress; D020011:Protective Agents / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use; D051436:Renal Insufficiency, Chronic / Q000378:metabolism / Q000517:prevention & control* / Q000652:urine*; D012084:Renin-Angiotensin System / Q000187:drug effects; D055815:Young Adult
chemical_list: C580711:15-F2alpha-isoprostane; D015415:Biomarkers; D006538:Heptanoic Acids; D028421:Isoprostanes; D020011:Protective Agents; D011758:Pyrroles; D000069059:Atorvastatin